Abstract
The high incidence of cardiovascular disease and colorectal cancer in the world's population means that these two conditions may coexist in the same patient. In addition fluoropyrimidines, backbone for the treatment of colorectal cancer in both early stage and advanced disease, have a well-characterized cardio-toxicity, which limits their use in patients with heart disease and limits their reintroduction in those patients who have shown this toxicity. For the treatment of this, increasing proportion of patients is now possible to consider fluoropyrimidines-free chemotherapy regimens that are examined in this work, with the attempt to provide a possible treatment algorithm for various situations encountered in clinical practice.
Keywords: Cardiovascular disease, cardiotoxicity, colorectal cancer, fluoropirymidines.
Related Journals
Applied Drug Research, Clinical Trials and Regulatory Affairs
37